IFNA1 and myeloid sarcoma: During the OLE, the proportion of patients with 24-week CDW from baseline remained significantly lower in MS patients receiving continuous ocrelizumab compared with those switching from IFN to ocrelizumab at the end of the core trials, being 16.1% vs 21.3% at the end of year 5 (p=0.014), with an HR for CDW during the OLE phase (i.e. with rebaselining at start of the OLE) of 1.06 (95% CI 0.8–1.41; p = 0.7) (Hauser et al., 2020).